Sign In
Buy GSK
$50.67
-1.48 (-2.84%)
At Close: Jun 18, 2026
GSK Expands Use Of Urinary Tract Infection Drug For Gonorrhoea Patients
11:12am, Friday, 12'th Dec 2025
GSK secures FDA approval for its oral gonorrhoea drug as EMA backs expanded RSV vaccine and additional respiratory treatments.
GSK Gets FDA Nod for Blujepa in Uncomplicated Urogenital Gonorrhea
11:10am, Friday, 12'th Dec 2025
GSK wins FDA approval for Blujepa, a new oral antibiotic treatment option for uncomplicated urogenital gonorrhea.
GSK gets EU regulator backing for expanded use of RSV vaccine
09:02am, Friday, 12'th Dec 2025
GSK said on Friday a panel of the European Medicines Agency had backed the use of its respiratory syncytial virus (RSV) vaccine, Arexvy, for all adults above the age of 18, paving the way for broader
European health regulator recommends approval for GSK's twice yearly asthma drug
08:58am, Friday, 12'th Dec 2025
The European Medicines Agency has recommended the approval of GSK's add-on drug to treat asthma and a chronic inflammatory sinus condition, the company said on Friday.
US FDA approves GSK's oral treatment for gonorrhea
12:35pm, Thursday, 11'th Dec 2025
The U.S. Food and Drug Administration on Thursday approved GSK's oral treatment for gonorrhea, a sexually transmitted infection.
GSK's Risvutatug Rezetecan Gets FDA's Orphan Drug Tag in Lung Cancer
12:06pm, Thursday, 11'th Dec 2025
GSK gains FDA Orphan Drug Designation for risvutatug rezetecan, adding momentum to its fast-advancing solid-tumor pipeline.
GSK Stock Up Almost 19% in 3 Months: Should You Buy, Hold or Sell?
10:15am, Thursday, 11'th Dec 2025
GSK's stock surge rides on strong Q3 results and raised guidance, as Specialty Medicines momentum offsets U.S. vaccine softness.
Here's Why GSK (GSK) is a Strong Value Stock
10:41am, Wednesday, 10'th Dec 2025
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
GSK drug for aggressive lung cancer wins US orphan status
03:09am, Wednesday, 10'th Dec 2025
GSK PLC (LSE:GSK, NYSE:GSK) has picked up another regulatory boost for its experimental cancer medicine risvutatug rezetecan, after the US Food and Drug Administration granted the treatment Orphan Dr
GSK drug for aggressive lung cancer wins US orphan status
03:06am, Wednesday, 10'th Dec 2025
GSK PLC (LSE:GSK, NYSE:GSK) has picked up another regulatory boost for its experimental cancer medicine risvutatug rezetecan, after the US Food and Drug...
Oxford, UK and San Jose, California , 10th December 2025 – Oxford BioTherapeutics (OBT), a clinical stage oncology company with a pipeline of immuno-oncology (IO) and Antibody Drug Conjugate (ADC)-b
Leading bank tips AstraZeneca as 2026's standout UK pharma, with GSK left trailing
07:33am, Monday, 08'th Dec 2025
JPMorgan has put AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) at the top of its UK healthcare picks for 2026, arguing that the company enters the new year with one of the most catalyst-rich pipelines in glo
Vaccine makers raise concerns over US panel's shift away from hepatitis B shots for newborns
01:35pm, Friday, 05'th Dec 2025
Vaccine makers expressed concern on Friday's decision by a U.S. advisory panel to scrap its long-standing recommendation that all infants receive a hepatitis B vaccine at birth, a shift that public he
Here's Why GSK (GSK) is a Strong Growth Stock
10:46am, Wednesday, 03'rd Dec 2025
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
BREAKING: Trump strikes major deal with UK on drug pricing
10:15am, Monday, 01'st Dec 2025
FOX Business White House correspondent Edward Lawrence reports the details of President Donald Trump's pharmaceutical deal with the U.K. on 'Varney & Co.'
